Transforming Human Heart Health.

Targeting cardiac disease simply, precisely, and safely with patient tailored cutting-edge biotechnological tools.

Technology

Organ-specific Gene Therapy Vectors

AaviGen leverages years of molecular and translational research for the development of novel organ-specific Adeno-Associated Viral vectors (AAV) on its unique next-CAP platform.

As a result, our proprietary portfolio of heart-specific vectors enables us to develop highly specific cardiac gene therapies with unprecedented safety.

Explore our Viral Vector Technology

Indications & Pipeline

Confronting Heart Failure

Heart Failure is a Pressing Concern.

With our team’s profound grasp of cardiac pathophysiology AaviGen seeks to revolutionise cardiac care by rectifying the aberrant cellular and molecular processes which underpin heart failure.

Explore our Indications & Pipeline

Heart Failure

Unmet Demand

64.3M

Patients worldwide are afflicted with heart failure.

Savarese et al. 2022

75%

5 year mortality rate, heart failure
mortality surpasses many cancers

Shah et al. 2017

5

1000

Of people with Heart Failure undergo heart transplantation.

Cook et al. 2015

News

The latest from AaviGen

Keep up to date with AaviGen’s events, research, publications, financing, and latest developments.

Explore our News

Want to get in touch?

If you want to learn more about our technology and programs, opportunities to collaborate, or you’re keen to join the AaviGen team, don’t hesitate to reach out to us.